American Society of Hematology

Figure 1.

$Figure 1. Progression-free and overall survival of 59 patients with relapsed or refractory B-cell lymphoma who received dosimetric and/or conventional therapeutic doses of Iodine-131-tositumomab (up to 75cGy whole body dose). / Reproduced with permission in modified form from Kaminski et al.30$

Progression-free and overall survival of 59 patients with relapsed or refractory B-cell lymphoma who received dosimetric and/or conventional therapeutic doses of Iodine-131-tositumomab (up to 75cGy whole body dose).

Reproduced with permission in modified form from Kaminski et al.³⁰

This Feature Is Available To Subscribers Only